CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 90 enrolled
Drug / intervention
Hysteroscopic myomectomyprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06768086
NCT06768086N/ACompleted

3 Months Preoperative Administration of Eutris Plus Prior Hysteroscopic Myomectomy: a Pilot Study

Centro di Ricerca Clinica Salentino·observational·Posted Jan 10, 2025·Updated Dec 4, 2025

In Brief

An observational study evaluating Hysteroscopic myomectomy for Uterine Fibroids and 4 related conditions. Completed, enrolled 90 participants across 1 site.

Detailed Summary

The administration of Epigallocatechin gallate (EGCG), Vitamin D and D-Chiro-Inositol (DCI) are effective in reducing the volume of fibroids and improving the symptoms of uterine fibroids. Since this benefit has been seen in laparoscopic myomectomy, a study was designed to see if there are positive effects in women undergoing hysteroscopic myomectomy. For this reason, patients were enrolled to undergo hysteroscopic myomectomy, then divided into two groups: patients to be treated preoperatively with a product based on Epigallocatechin gallate (EGCG), Vitamin D and D-Chiro-Inositol (DCI) for 3 months before myomectomy and patients not to be treated before surgery. All clinical and surgical parameters were then collected and analyzed to verify the differences between the two groups (treated women VS untreated women).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedJan 10, 2025
Enrollment StartFeb 1, 2025
Primary CompletionSep 30, 2025
Study CompletionNov 25, 2025
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 1.5 years ago

Interventions

Hysteroscopic myomectomyprocedure

The hysteroscopic myomectomies were conducted during the follicular phase of the menstrual cycle. Throughout the surgical procedure, the intrauterine pressure was meticulously maintained at less than 80 mm Hg. Data on the duration of the surgical intervention, the volume of fluid administered, and the volume of fluid absorbed were collected. Complete resection was characterized as the total excision of the myoma. The determination of the completeness of myomectomy was made by the experienced surgeon during the surgical process. In instances where the resection was deemed incomplete, the decision to pursue a secondary surgical intervention was predicated on ultrasonographic evaluations, the symptomatic presentation of the patients, and, in certain circumstances, the findings from diagnostic hysteroscopy. Cases in which access to the uterine cavity was unfeasible were classified as "failed procedures" and were subsequently excluded from the study.